

Clinical trial data on immunotherapy for metastatic melanoma shows significant improvement in overall survival. Checkpoint inhibitors, such as pembrolizumab, work by blocking the PD-1 pathway, thereby enabling the patient's own T-cells to attack cancer cells more effectively.